🇺🇸 FDA
Patent

US 12295362

Formulations and processes for CAR T cell drug products

granted A61KA61K40/11A61K40/31

Quick answer

US patent 12295362 (Formulations and processes for CAR T cell drug products) held by Allogene Therapeutics, Inc. expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Allogene Therapeutics, Inc.
Grant date
Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4211